氘丁苯那嗪治疗抗精神病药引起的迟发性运动障碍1例

Deutetrabenazine in the treatment of tardive dyskinesia induced by antipsychotics:a case report

迟发性运动障碍(tardive dyskinesia,TD)是抗精神病药治疗过程中常见的不良反应。氘丁苯那嗪于2017年被FDA批准用于治疗TD,目前该药刚在中国上市,国内关于此药的临床应用鲜有报道。本例19岁女性,诊断"精神分裂症",长期服用抗精神病药后近来出现无故张嘴伸舌,头颈后仰,咀嚼困难,讲话口齿不清,流口水等症状,诊断"TD",予调整药物及维生素E、氯硝西泮等对症治疗效果欠佳,予氘丁苯那嗪治疗后症状逐渐减轻,治疗效果确切。本文通过对该病例的报道,以期为临床工作提供参考和经验。

Tardive dyskinesia(TD)is a common adverse reaction during the treatment of antipsychotic drugs and there is no satisfactory treatment for it.Deutetrabenazine has been approved by FDA in 2017 to treat TD.This drug has just been launched in China and there are few reports on its clinical application in China.This article reports a 19-year-old female diagnosed with"schizophrenia".She has taken antipsychotics for a long time.Recently,she had symptoms such as the opening mouth and sticking tongue out,head and neck receding,difficulty chewing,slurred speech,drooling,etc.and was diagnosed with"TD".She was adjusted for drugs and was prescribed vitamin E and clonazepam.The therapeutic effect of this symptomatic treatment was poor.After being treated with Deutetrabenazine,her symptoms gradually alleviated and the therapeutic effect was definite.This case report will provide references and experience for clinical work.